CM
SUPN icon

Caption Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Caption Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-50,000
Closed -$1.66M – 720
2018
Q4 		$1.66M Buy
+50,000
New +$2.15M 0.13% 205

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caption Management's SUPN Position: Q4 2025 in Review

Caption Management sold out of Supernus Pharmaceuticals (SUPN) in Q4 2025, closing a stake of 28,341 shares — an estimated $1.38M sold.

Caption Management first reported a position in SUPN in Q4 2018 and held it in 5 quarters. The position peaked at $1.46M in Q4 2020. 333 funds tracked by Wall St. Rank hold SUPN as of Q4 2025.

  • Caption Management reported no remaining Supernus Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Caption Management sold 28,341 Supernus Pharmaceuticals shares in Q4 2025, an estimated $1.38M.
  • Caption Management first reported a position in Supernus Pharmaceuticals in Q4 2018 and held it in 5 quarters.
  • Caption Management's Supernus Pharmaceuticals position peaked at $1.46M in Q4 2020.
  • 333 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2025.

Based on Caption Management's 13F filing for Q4 2025, filed 17 Feb 2026.